The first-ever treatment for Alexander disease approved in the USA

Zilganersen (Zanvastro™) is the first treatment for Alexander disease (AxD) for both adults and children. This leukodystrophy affects approximately 1 in 3 million children (Japanese estimate).

When the disease manifests, it attacks the myelin, the protective sheath surrounding the nervous system. Symptoms can sometime develop rapidly: cognitive impairment, epilepsy, motor impairment, and neurological symptoms that appear almost overnight…

This approval by the Federal Drug Administration (FDA) in the US marks a crucial milestone for patients and their families. ELA International is now focused on making this treatment more widely available across Europe as soon as possible.